Words by Jade Williams
Ireland has launched its first national clinical genomics study in paediatric oncology, by key stakeholders from the country’s healthcare, life sciences and academic research sectors.
The Molecular and Genomic Interrogation of Childhood Cancer – Ireland (MAGIC-I) study is a five-year project aiming to integrate advanced genetic and genomic profiling with data science to optimise treatment pathways for children with cancer.
MAGIC-I will set out to establish a framework for deep genomic interrogation across all paediatric oncology cases in Ireland, by embedding computational biology and sequencing technologies into routine clinical practice. Eventually, the study seeks to enable real-time, evidence-based precision interventions for these patients.
Dr Colm Henry, Chief Clinical Officer, Health Service Executive, commented in a press release that the launch “is a great example for the vision of introducing genome sequencing and accompanying research into clinical care”.
The study is a collaborative effort, specifically involving Systems Biology Ireland (SBI), Children’s Health Ireland hospitals, Precision Oncology Ireland and industry partners.
“I cannot emphasise enough how big of a signal this is for the Irish healthcare system and likely also beyond it,” commented Prof Walter Kolch, Director, SBI. “Importantly, it steps up to a global ambition in its seamless amalgamation of clinical research with advanced computational modelling. It is a trailblazer in incorporating new concepts for personalised medicine, such as digital twins, and for hand-in-glove cooperation between clinical research and cutting-edge computational modelling, which is still very unique.”
It is hoped that the study will provide advancements in precision and personalised approaches for cancer diagnosis and care, both within the country and ultimately, beyond.
